Clinical trials: Cancer Patients, open to volunteers
Ion Beam Radiation Therapy for Tumor Patients
Ion Therapy Patient Registry
The purpose of the study is the prospective and standardized data collection of patients treated with ion therapy at MedAustron.
- Trial name
- REGI-MA-002015 (NCT03049072)
- Testing
- Protons and Carbon Ions
- Where
- Austria
- Volunteers
- 2,800 people
- Sponsor
- EBG MedAustron GmbH
Sarcopenia, Breast Cancer
Exercise Intervention for Breast Cancer Patients With Sarcopenia
Sarcopenia is a common yet underrecognized complication in breast cancer survivors during rehabilitation, characterized by loss of muscle mass, reduced muscle strength, and impaired physical function, which adversely affects…
- Trial name
- EX-BCSarc (NCT07732101)
- Testing
- "Exercise for Muscle Health" Program
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Capital Medical University
GBM, Glioblastoma Multiforme (GBM)
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
The goal of this clinical trial is to evaluate the safety and feasibility of focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption using the Next Generation Dome Helmet (NGDH) in adults with glioblastoma (GBM)…
- Conditions
- GBM, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme of Brain, Glioblastoma Multiforme Glioma
- Trial name
- NCT07179328
- Testing
- Focused Ultrasound Next Generation Dome Helmet, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Gastric Cancer
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma that failed to be treated…
- Trial name
- NCT06417892
- Testing
- PD-1inhibitor, Fruquintinib, albumin paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Triple Negative Breast Cancer
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer…
- Trial name
- NCT05909332
- Testing
- Antivascular therapy, Chemotherapy
- Where
- 15 sites in China
- Volunteers
- 764 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
NSCLC, Adjuvant Drug Therapy
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers. Approximately 30-40% of East Asian adenocarcinoma patients harbor EGFR mutations.
- Conditions
- NSCLC, Adjuvant Drug Therapy, EGFR
- Trial name
- NCT07181499
- Testing
- Befotertinib, Pemetrexed + Carboplatin
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Glioma
The circTeloDIAG: Liquid Biopsy for Glioma Tumor
Gliomas represent the most frequent primary brain tumor, with 2,500 to 3,000 new cases per year in France. Their diagnosis, although highly complex, is essential for determining patient management.
- Trial name
- circTeloDIAG (NCT04931732)
- Testing
- ctDNA analysis
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
The goal of this clinical trial is to evaluate whether adjuvant darolutamide plus androgen-deprivation therapy (ADT) can reduce post-operative recurrence and improve disease control in high-risk prostate cancer patients-defined…
- Trial name
- NCT07282197
- Testing
- Darolutamide (BAY 1841788)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University First Hospital
Lung Cancer, Venous Thromboembolism
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint…
- Conditions
- Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06950697
- Where
- 5 sites in China
- Volunteers
- 2,400 people
- Sponsor
- Beijing Chao Yang Hospital
Osteosarcoma, Sarcoma
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT05830123
- Testing
- HS-20093
- Where
- 11 sites in China
- Volunteers
- 170 people
- Sponsor
- Hansoh BioMedical R&D Company
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
This is an exploratory study to assess [18F]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial.
- Trial name
- NCT04989959
- Testing
- [18F]PT2385, Positron Emission Tomography/Computed Tomography, Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Orhan Kemal Oz
Breast Cancer Female
Dermatitis During Adjuvant Irradiation for BREAst Cancer:
In the randomized DAI-BREAC trial, a reminder app will be prospectively tested that reminds breast cancer patients four times each day to perform the required skin care.
- Trial name
- DAI-BREAC (NCT06483477)
- Testing
- Standard skin care, Reminder App
- Where
- 5 sites in Denmark, Germany
- Volunteers
- 268 people
- Sponsor
- University Hospital Schleswig-Holstein
Advanced Solid Tumors Cancer
First-In-Human Study of KHN922 for Injection
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
- Trial name
- NCT07514975
- Testing
- KHN922 for injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Acute Myeloid Leukemia (AML)
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate…
- Trial name
- NCT05907057
- Testing
- Ivosidenib 500mg Oral Tablet, Azacitidine
- Where
- 15 sites in Austria, France and 2 more
- Volunteers
- 245 people
- Sponsor
- Servier Affaires Médicales
Muscle-invasive Bladder Cancer
Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy
In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored.
- Trial name
- NCT07440901
- Testing
- Immunotherapy plus chemotherapy
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer.
- Trial name
- NCT05242965
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Breast cancer is one of the world's most common cancers in females. Most of the chemotherapy protocols used to treat breast cancer involve doxorubicin. Doxorubicin has a very significant antitumor effect on breast tumors.
- Conditions
- Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin, Doxorubicin Adverse Reaction
- Trial name
- NICBREASTRCT (NCT07897409)
- Testing
- Nicorandil Oral Tablet, Adriamycin (Doxorubicin)
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Universiti Sains Malaysia
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT03606967
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 30 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.